NeuroPace (NPCE) Scheduled to Post Quarterly Earnings on Wednesday

NeuroPace (NASDAQ:NPCE) is set to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect NeuroPace to post earnings of ($0.32) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, March 5th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.10. The company had revenue of $18.01 million during the quarter, compared to analyst estimates of $17.74 million. NeuroPace had a negative return on equity of 153.76% and a negative net margin of 50.38%. On average, analysts expect NeuroPace to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroPace Trading Down 1.2 %

Shares of NASDAQ NPCE opened at $13.47 on Tuesday. NeuroPace has a 12-month low of $3.80 and a 12-month high of $18.15. The company has a market cap of $386.86 million, a price-to-earnings ratio of -10.52 and a beta of 2.06. The company has a current ratio of 5.71, a quick ratio of 5.02 and a debt-to-equity ratio of 2.76. The stock’s 50 day simple moving average is $13.98 and its 200 day simple moving average is $11.92.

Insider Buying and Selling at NeuroPace

In other news, major shareholder Orbimed Advisors Llc sold 461,899 shares of the business’s stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $14.49, for a total value of $6,692,916.51. Following the sale, the insider now owns 3,542,068 shares of the company’s stock, valued at approximately $51,324,565.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders sold 525,345 shares of company stock valued at $7,583,250. 27.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

NPCE has been the subject of several analyst reports. SVB Leerink initiated coverage on shares of NeuroPace in a report on Tuesday, January 30th. They set an “outperform” rating and a $22.00 price target for the company. Morgan Stanley lifted their price target on NeuroPace from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Wednesday, March 6th. Cantor Fitzgerald increased their price objective on NeuroPace from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Leerink Partnrs reaffirmed an “outperform” rating on shares of NeuroPace in a research note on Tuesday, January 30th. Finally, Wells Fargo & Company raised NeuroPace from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $16.00 to $20.00 in a research note on Thursday, March 14th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, NeuroPace currently has an average rating of “Moderate Buy” and a consensus price target of $15.67.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.